LATTICE Trademark

Trademark Overview


On Thursday, March 11, 2021, a trademark application was filed for LATTICE with the United States Patent and Trademark Office. The USPTO has given the LATTICE trademark a serial number of 90574267. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 25, 2024. This trademark is owned by Ambry Genetics Corporation. The LATTICE trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Providing genomic, imaging and pathology data being medical information and medical analyses based on collected clinical and research information in the field of cancer and other diseases for medical purposes; analysis of cells, tissues, gene expressions, gene sequences, genome annotation, transcriptome characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; preparation of reports relating to gene expressions, gene and genome sequences, genome interaction and annotation, transcriptome analysis and characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of arc...

Consulting services relating to scientific and medical research concerning genomic, imaging, pathology and clinical data; designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine; clinical research in the fields of de-risking clinical trial or study designs, clinical trials simulations and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic, imaging, pathology and clinical data; medical and scientific research, namely, conducting laboratory testing for clinical trials of pharmaceuticals and medical devices in humans; health care services, namely, medical laboratory services and cli...
lattice

General Information


Serial Number90574267
Word MarkLATTICE
Filing DateThursday, March 11, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 28, 2022

Trademark Statements


Goods and ServicesProviding genomic, imaging and pathology data being medical information and medical analyses based on collected clinical and research information in the field of cancer and other diseases for medical purposes; analysis of cells, tissues, gene expressions, gene sequences, genome annotation, transcriptome characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; preparation of reports relating to gene expressions, gene and genome sequences, genome interaction and annotation, transcriptome analysis and characterization, and genome mapping for medical diagnosis and treatment of cancer, neurological disease, respiratory disease, inflammatory disease, and mitochondrial disease; medical assistance services in the nature of genetic and medical information provided to medical professionals from remote locations via the internet and global computer networks through the use of archived genome sequence information, medical images, diagnostic test results, and a data storage and retrieval system; medical genetic testing consultations provided via phone, online chat or videoconferencing; medical diagnostic testing, monitoring and reporting services; medical imaging services; medical information; medical screening; medical testing for diagnostic purposes; multi-disciplinary, integrative, genetic consultations for medical treatment purposes; providing a website featuring genetic and medical information; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged and accessed in real-time by users; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via electronic patient monitoring devices that feed information to the website that can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions; providing medical profiles and medical record analysis and assessments via a website that are designed to provide custom tailored outputs about recommended resources and treatments associated with a defined set of symptoms, concerns, genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; providing medical testing and medical consultations to individuals and their physicians to help them make health, wellness and nutritional changes in their daily living to improve health; providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms based on genome sequencing analysis, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; provision of health care and medical services by health care professionals via the internet or telecommunication networks; remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes; health assessment services, namely, providing assessment of risk of disease and providing health monitoring of individuals all through use of genome sequencing analysis and reporting, microbiome sequencing analysis, metabolome analysis, advanced clinical imaging, laboratory tests, and medical imaging and DNA screening; all for medical treatment and diagnostic purposes
Goods and ServicesConsulting services relating to scientific and medical research concerning genomic, imaging, pathology and clinical data; designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine; clinical research in the fields of de-risking clinical trial or study designs, clinical trials simulations and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic, imaging, pathology and clinical data; medical and scientific research, namely, conducting laboratory testing for clinical trials of pharmaceuticals and medical devices in humans; health care services, namely, medical laboratory services and clinical scientific laboratory services for testing clinical specimens for the purpose of providing information for medical research, clinical trials, and pre-clinical investigations; clinical research in the fields of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; clinical research, namely, accessing and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, enriching and enhancing clinical trial or study designs in the nature of research and development in the field of medicine, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; conducting drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses in the nature of medical research, and pharmaceutical development, in the fields of omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, all related to the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation; medical research in the nature of disease diagnoses and treatment determination, selection, and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and accessing, processing, and analyzing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and services all in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field using artificial intelligence, machine learning, supervised machine learning, unsupervised machine learning, deep learning, statistical learning, data mining, big data analytics, predictive analytics, predictive modeling, multivariate analytics, precision medicine, bioinformatics, modeling, and simulation for others

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, May 25, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 11, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmbry Genetics Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAliso Viejo, CA 92656

Party NameAmbry Genetics Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAliso Viejo, CA 92656

Trademark Events


Event DateEvent Description
Monday, March 25, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 25, 2024ABANDONMENT - NO USE STATEMENT FILED
Thursday, October 26, 2023ASSIGNED TO EXAMINER
Thursday, June 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 13, 2023SOU EXTENSION 2 GRANTED
Tuesday, June 13, 2023SOU EXTENSION 2 FILED
Tuesday, June 13, 2023SOU TEAS EXTENSION RECEIVED
Thursday, January 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 24, 2023SOU EXTENSION 1 GRANTED
Tuesday, January 24, 2023SOU EXTENSION 1 FILED
Tuesday, January 24, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 23, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 28, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 28, 2022PUBLISHED FOR OPPOSITION
Thursday, June 23, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, June 8, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 25, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 25, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, May 25, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, May 25, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, May 25, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, May 9, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, May 9, 2022FINAL REFUSAL E-MAILED
Monday, May 9, 2022FINAL REFUSAL WRITTEN
Tuesday, April 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 4, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 7, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 7, 2021NON-FINAL ACTION E-MAILED
Thursday, October 7, 2021NON-FINAL ACTION WRITTEN
Wednesday, October 6, 2021ASSIGNED TO EXAMINER
Friday, June 11, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 15, 2021NEW APPLICATION ENTERED